AI Article Synopsis
- The CardioMEMS HF System is an approved device for monitoring heart failure in adults, helping to cut down hospital visits and enhance quality of life for certain patients.
- It works by being implanted in the body to measure pulmonary arterial pressure, with data sent wirelessly to healthcare providers for remote adjustments in treatment.
- While it shows promise for patients with congenital heart disease, more extensive studies are needed to confirm its effectiveness in this group.
Article Abstract
The CardioMEMS HF System (Abbott, Abbott Park, IL) is the first FDA- and CE-Mark-approved device for monitoring patients with heart failure, significantly reducing hospitalizations and improving the quality of life for NYHA class III non-congenital adult patients. This device, implanted percutaneously, allows the direct monitoring of pulmonary arterial pressure with the wireless transfer of pressure data to the clinician, who can adjust the therapy remotely. Limited experience exists regarding its use in patients with congenital heart disease (CHD). CardioMEMS device implantation is feasible and safe in selected adults and children with CHD. The potential of the device to reduce heart failure hospitalizations in this population is enormous, but further multi-center studies are needed to demonstrate its efficacy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277830 | PMC |
| http://dx.doi.org/10.3390/jcm13144234 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Remote Management of Heart Failure in Patients with Implantable Devices.
Diagnostics (Basel)
November 2024
Cardiology Department, GB Grassi Hospital, ASL Roma 3, 00122 Rome, Italy.
: Heart failure (HF) is a chronic disease with a steadily increasing prevalence, high mortality, and social and economic costs. Furthermore, every hospitalization for acute HF is associated with worsening prognosis and reduced life expectancy. In order to prevent hospitalizations, it would be useful to have instruments that can predict them well in advance.
View Article and Find Full Text PDFCardioMEMS as an aid to the management of a pregnant patient with peripartum Cardiomyopathy: A case report.
Eur J Obstet Gynecol Reprod Biol
December 2024
Division of Cardiology, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, United States.
Article Synopsis
- * The CardioMEMS device provided real-time data on her heart health, enabling healthcare providers to make timely adjustments to her treatment plan, which helped maintain her stability during pregnancy.
- * The report emphasizes the advantages of using the CardioMEMS system in high-risk pregnancies, showcasing that the patient avoided hospital admissions and successfully delivered a healthy baby vaginally.
Remote haemodynamic-guided heart failure management in France: Results from the CardioMEMS HF System Post-Market Study (COAST) French cohort.
Arch Cardiovasc Dis
November 2024
PhyMedExp, Inserm, CNRS, Cardiology Department, INI-CRT, université de Montpellier, 34295 Montpellier, France.
Article Synopsis
- The study evaluated the CardioMEMS™ HF System in 103 French patients to assess its feasibility, safety, and clinical benefits post-implantation.
- Over two years, no device-related complications were reported, and the system showed a 50% reduction in heart failure hospitalizations compared to the year before implantation.
- Additionally, patients experienced lower pulmonary artery pressures and improvements in their functional class and overall quality of life.
Hemodynamic Monitoring of Pediatric Patients With Heart Failure and Pulmonary Hypertension Using CardioMEMS.
J Soc Cardiovasc Angiogr Interv
June 2024
Department of Pediatric Cardiology, Hospital Universitario La Paz, Madrid, Spain.
Background: The CardioMEMS is an implantable device for hemodynamic monitoring approved by the US Food and Drug Administration for adult patients with heart failure. It has been used in the adult population without structural heart disease and with congenital heart diseases, but we do not have data in the pediatric population.
Methods: We report the initial single-center experience of the CardioMEMS implantation in children.
Article Synopsis
- The CardioMEMS HF System is an approved device for monitoring heart failure in adults, helping to cut down hospital visits and enhance quality of life for certain patients.
- It works by being implanted in the body to measure pulmonary arterial pressure, with data sent wirelessly to healthcare providers for remote adjustments in treatment.
- While it shows promise for patients with congenital heart disease, more extensive studies are needed to confirm its effectiveness in this group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!